TRIM21 Knockout A-549 Cell Line
Cat.No.:
EDC07660
Species:
Human
Cell Name:
A-549
Gene:
TRIM21
Gene ID:
6737
Size:
1×10⁶cells
TRIM21 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07660 |
|---|---|
| Product Name | TRIM21 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | TRIM21 |
| NCBI Gene ID | |
| Gene Synonyms | RNF81|RO52|Ro/SSA|SSA|SSA1 |
| Summary |
This gene encodes a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The encoded protein is part of the RoSSA ribonucleoprotein, which includes a single polypeptide and one of four small RNA molecules. The RoSSA particle localizes to both the cytoplasm and the nucleus. RoSSA interacts with autoantigens in patients with Sjogren syndrome and systemic lupus erythematosus. Alternatively spliced transcript variants for this gene have been described but the full-length nature of only one has been determined. [provided by RefSeq, Jul 2008]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying TRIM21 function, TRIM21 Knockout A-549 Cell Line or TRIM21 overexpression A-549 Cell Line?
The choice depends on whether you are studying TRIM21's role in intracellular antiviral immunity, particularly in the respiratory pathogen context. The Knockout line is the appropriate tool for asking whether TRIM21 is required for antibody-dependent neutralization of viruses that infect respiratory epithelium. Overexpression is useful for testing whether elevated TRIM21 enhances antibody-mediated neutralization, particularly relevant for emerging respiratory pathogens.
For respiratory virus research, the EDITGENE TRIM21 Knockout in A-549 is particularly valuable — A-549 supports replication of many respiratory viruses (adenovirus, influenza, SARS-CoV-2), enabling direct testing of TRIM21's protective antiviral functions in a disease-relevant cellular context. Rescue with wild-type or RING-dead TRIM21 is the standard approach for distinguishing antibody-binding from E3 ligase functions.
What are the application scenarios for this model?
Primary applications:
• Respiratory virus neutralization: TRIM21-dependent antibody-mediated neutralization assays for viruses that infect respiratory epithelium (adenovirus, influenza, SARS-CoV-2).
• Antibody-coated virus clearance: imaging-based analysis of virus-antibody complex degradation kinetics in the absence of TRIM21.
• Innate immune signaling: NF-κB and IRF3 activation downstream of TRIM21-mediated K63-ubiquitin signaling during viral infection.
• Therapeutic antibody efficacy: assessment of how TRIM21 status influences the intracellular efficacy of therapeutic antibodies in a respiratory disease-relevant cellular context.
EDITGENE recommends this model for researchers investigating antibody-mediated antiviral immunity in respiratory virus infection contexts.
Is this TRIM21 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. TRIM21 rescue experiments in A-549 are particularly suited to antiviral immunity studies:
• Construct design: use a codon-modified TRIM21 sequence with a C-terminal tag (FLAG, HA). Standard TRIM21 expression vectors work well in A-549.
• Antiviral function rescue: the principal functional readout for A-549 context is restoration of antibody-mediated intracellular virus neutralization — assays should use antibody-coated virus challenge (adenovirus is the canonical TRIM21 substrate).
• Structure-function variants: RING-dead (C16/15A) and Fc-binding-deficient (H433A) TRIM21 dissect E3 ligase versus antibody-binding functions in the respiratory virus infection context.
• Functional readout: viral replication assays in rescue cells compared to knockout and parental lines, with and without virus-specific antibody, quantify TRIM21's antiviral contribution.
A-549 transduces with lentivirus at standard efficiency for adherent cancer lines and supports stable TRIM21 rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Related Publications
NMI Facilitates Influenza A Virus Infection by Promoting Degradation of IRF7 through TRIM21.
IF=5.3
American journal of respiratory cell and molecular biology
Acute respiratory infections caused by influenza A virus (IAV) spread widely and lead to substantial morbidity and mortality. Host cell induction of type I interferon (IFN-I) plays a fundamental role in eliminating the virus during the innate antiviral response. The potential role of N-myc and STAT interactor (NMI) and its underlying mechanisms of action during IAV infection, however, remain elusive. In this study, we found that the expression of NMI increased after IAV infection. -knockout mice infected with IAV displayed increased survival rate, decreased weight loss, lower viral replication, and attenuated lung inflammation when compared with wild-type mice. Deficiency of NMI promoted the production of IFN-I and IFN-stimulated genes and . Reduced levels of NMI also resulted in an increase of the expression of IFN regulator factor (IRF) 7. Further studies have revealed that NMI could interact with IRF7 after IAV infection, and this interaction involved its NID1 and NID2 domain. In addition, NMI facilitated ubiquitination and proteasome-dependent degradation of IRF7 through recruitment of the E3 ubiquitin ligase TRIM21 (tripartite motif-containing 21) to limit the IAV-triggered innate immunity. Our findings reveal a clearer understanding of the role of NMI in regulating the host innate antiviral response and provide a potential therapeutic target for controlling IAV infection.
IRGM Inhibits the AKT/mTOR Signaling Pathway by Interacting with TRIM21 to Alleviate Sepsis-Induced Acute Lung Injury.
IF=5
Inflammation
Acute lung injury (ALI) is a severe complication of sepsis, and its underlying pathological mechanisms remain poorly understood. This study aims to investigate the role and mechanisms by which IRGM mediates autophagy through the regulation of the AKT/mTOR signaling pathway in sepsis-induced ALI. Initially, a sepsis-induced ALI mouse model was established using cecal ligation and puncture (CLP). Our results demonstrated that Irgm1 expression was significantly upregulated in the ALI model. Subsequently, Irgm1 was knocked down in vivo using AAV vectors, and changes in ALI symptoms were assessed. In vitro, a sepsis-induced ALI cell model was generated by stimulating A549 cells with lipopolysaccharide (LPS). The effects of IRGM overexpression on autophagy and apoptosis were evaluated, and its impact on the AKT/mTOR signaling pathway was analyzed. Furthermore, mass spectrometry and co-immunoprecipitation (COIP) experiments were conducted to explore the interaction between IRGM and TRIM21. In vivo results showed that Irgm1 knockout exacerbated CLP-induced ALI, as evidenced by a significant reduction in autophagic activity, increased apoptosis, and aberrant activation of the AKT/mTOR pathway. Further cellular experiments suggested that IRGM may enhance autophagy by inhibiting the AKT/mTOR signaling pathway, thereby attenuating LPS-induced cell damage. Additionally, COIP experiments revealed that IRGM interacts with TRIM21 to inhibit AKT/mTOR pathway activation, thereby promoting autophagy and mitigating sepsis-induced ALI. In conclusion, IRGM regulates autophagy through the AKT/mTOR signaling pathway and exerts protective effects in sepsis-induced ALI, suggesting that it may serve as a potential therapeutic target for sepsis-related ALI.
download